ZA99133B - Transgenic rabbit that expresses a functional human lipoprotein (A). - Google Patents

Transgenic rabbit that expresses a functional human lipoprotein (A).

Info

Publication number: ZA99133B
Authority: ZA; South Africa
Prior art keywords: expresses; rabbit; functional human; transgenic rabbit; human lipoprotein
Prior art date: 1998-01-08

Application number

ZA9900133A

Other languages

English (en)

Inventor

Didier Rouy

Nicolas Duverger

Florence Emmanuel

Patrice Denefle

Louis-Marie Houdebine

Celine Viglietta

Edward M Rubin

Steven D Hughes

Original Assignee

Rhone Poulenc Rorer Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-08

Filing date

1999-01-08

Publication date

1999-09-16

1999-01-08 Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma

1999-09-16 Publication of ZA99133B publication Critical patent/ZA99133B/xx

Links

241000283973 Oryctolagus cuniculus Species 0.000 title abstract 4
230000009261 transgenic effect Effects 0.000 title abstract 2
101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 title 1
102000045903 human LPA Human genes 0.000 title 1
102100040214 Apolipoprotein(a) Human genes 0.000 abstract 3
101710095342 Apolipoprotein B Proteins 0.000 abstract 1
102100040202 Apolipoprotein B-100 Human genes 0.000 abstract 1
101710115418 Apolipoprotein(a) Proteins 0.000 abstract 1
108010012927 Apoprotein(a) Proteins 0.000 abstract 1
108010033266 Lipoprotein(a) Proteins 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Environmental Sciences (AREA)
Biotechnology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Husbandry (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biodiversity & Conservation Biology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Diabetes (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Microbiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Plant Pathology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pathology (AREA)

ZA9900133A 1998-01-08 1999-01-08 Transgenic rabbit that expresses a functional human lipoprotein (A). ZA99133B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US7072798P	1998-01-08	1998-01-08

Publications (1)

Publication Number	Publication Date
ZA99133B true ZA99133B (en)	1999-09-16

Family

ID=22097023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9900133A ZA99133B (en)	1998-01-08	1999-01-08	Transgenic rabbit that expresses a functional human lipoprotein (A).

Country Status (12)

Country	Link
US (1)	US6512161B1 (ja)
EP (1)	EP1049767B1 (ja)
JP (2)	JP2002500039A (ja)
AT (1)	ATE302267T1 (ja)
AU (1)	AU759707B2 (ja)
CA (1)	CA2316808C (ja)
DE (1)	DE69926729T2 (ja)
DK (1)	DK1049767T3 (ja)
ES (1)	ES2247780T3 (ja)
PT (1)	PT1049767E (ja)
WO (1)	WO1999035241A1 (ja)
ZA (1)	ZA99133B (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1122314A1 (en) *	2000-02-04	2001-08-08	Leja Research B.V.	Method for the production of a protein
US7888324B2 (en)	2001-08-01	2011-02-15	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
US7407943B2 (en) *	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7259150B2 (en) *	2001-08-07	2007-08-21	Isis Pharmaceuticals, Inc.	Modulation of apolipoprotein (a) expression
AU2012258396B2 (en) *	2001-08-07	2015-05-07	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US7227014B2 (en) *	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
DK1534320T3 (da)	2002-08-02	2007-04-02	Univ Bruxelles	Apolipoprotein L-I til behandling af trypanosomen sygdomme
US20040033480A1 (en) *	2002-08-15	2004-02-19	Wong Norman C.W.	Use of resveratrol to regulate expression of apolipoprotein A1
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
US20060009410A1 (en) *	2002-11-13	2006-01-12	Crooke Rosanne M	Effects of apolipoprotein B inhibition on gene expression profiles in animals
CA2556697C (en) *	2004-02-17	2018-01-09	Nielsen Media Research, Inc.	Methods and apparatus for monitoring video games
US20050287558A1 (en) *	2004-05-05	2005-12-29	Crooke Rosanne M	SNPs of apolipoprotein B and modulation of their expression
PT2409713E (pt) *	2004-08-10	2015-10-09	Genzyme Corp	Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos
WO2006045010A2 (en) *	2004-10-20	2006-04-27	Resverlogix Corp.	Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP2314295B1 (en) *	2005-07-29	2015-01-28	Resverlogix, Inc	Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
ES2386578T3 (es)	2006-05-05	2012-08-23	Isis Pharmaceuticals, Inc.	Compuestos y procedimientos para modular la expresión de PCSK9
MX2009008099A (es) *	2007-02-01	2009-12-14	Resverlogix Corp	Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
CN101679979A (zh) *	2007-03-24	2010-03-24	基酶有限公司	施用与人载脂蛋白b互补的反义寡核苷酸
KR101629356B1 (ko)	2008-06-26	2016-06-13	리스버로직스 코퍼레이션	퀴나졸리논 유도체의 제조방법
US20110023140A1 (en) *	2008-12-04	2011-01-27	Sigma-Aldrich Co.	Rabbit genome editing with zinc finger nucleases
CA2747417C (en)	2009-01-08	2017-01-03	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular disease
WO2010107838A1 (en)	2009-03-16	2010-09-23	Isis Pharmaceuticals, Inc.	Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
US9238640B2 (en)	2009-03-18	2016-01-19	Resverlogix Corp.	Anti-inflammatory agents
BRPI1014956B8 (pt)	2009-04-22	2021-05-25	Resverlogix Corp	agentes anti-inflamatórios
CA2770825A1 (en)	2009-08-13	2011-02-17	Crystal Bioscience Inc.	Transgenic animal for production of antibodies having minimal cdrs
WO2012141280A1 (ja)	2011-04-15	2012-10-18	国立大学法人大阪大学	Ｄｎａワクチン
JP5992049B2 (ja)	2011-11-01	2016-09-14	レスバーロジックスコーポレイション	置換されたキナゾリノンのための経口速放性製剤
WO2013173789A2 (en)	2012-05-17	2013-11-21	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions
US9574193B2 (en)	2012-05-17	2017-02-21	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein (a) expression
DK2855500T3 (da) *	2012-05-24	2020-09-14	Ionis Pharmaceuticals Inc	Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression
JP6001974B2 (ja)	2012-09-21	2016-10-05	アンジェスＭｇ株式会社	アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
WO2014080290A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en)	2012-12-21	2014-06-26	Rvx Therapeutics Inc.	Novel heterocyclic compounds as bromodomain inhibitors
US9018437B2 (en)	2013-09-12	2015-04-28	Matthias W. Rath	Transgenic mouse expressing human apo(a) and human apo(B-100) with disabled vitamin C gene produces human Lp(a)
EP3021663B1 (en) *	2014-10-05	2023-01-18	Matthias W. Rath	Transgenic mouse expressing human lipoprotein (a) with disabled vitamin c gene
JP6903585B2 (ja)	2015-03-13	2021-07-14	レスバーロジックスコーポレイション	補体関連疾患の治療のための組成物および治療方法
EP4237561A1 (en)	2020-12-23	2023-09-06	Argonaute Rna Limited	Treatment of cardiovascular disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0467349B1 (en)	1983-10-20	2000-12-27	The Research Foundation Of State University Of New York	Regulation of gene expression by employing translational inhibition utilizing mRNA interfering complementary RNA
GB8424757D0 (en)	1984-10-01	1984-11-07	Pasteur Institut	Retroviral vector
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US4861719A (en)	1986-04-25	1989-08-29	Fred Hutchinson Cancer Research Center	DNA constructs for retrovirus packaging cell lines
AU3069189A (en)	1988-02-05	1989-08-25	Trustees Of Columbia University In The City Of New York, The	Retroviral packaging cell lines and processes of using same
WO1990002806A1 (en)	1988-09-01	1990-03-22	Whitehead Institute For Biomedical Research	Recombinant retroviruses with amphotropic and ecotropic host ranges
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
CA2039921A1 (en)	1990-04-16	1991-10-17	Xandra O. Breakefield	Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
AU7906691A (en)	1990-05-23	1991-12-10	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
US5252479A (en)	1991-11-08	1993-10-12	Research Corporation Technologies, Inc.	Safe vector for gene therapy
EP0651805B1 (en)	1992-07-17	2006-12-13	Dana Farber Cancer Institute	Method of intracellular binding of target molecules
WO1994012649A2 (en)	1992-12-03	1994-06-09	Genzyme Corporation	Gene therapy for cystic fibrosis
US5434058A (en) *	1993-02-09	1995-07-18	Arch Development Corporation	Apolipoprotein B MRNA editing protein compositions and methods
FR2705361B1 (fr)	1993-05-18	1995-08-04	Centre Nat Rech Scient	Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr)	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5866755A (en)	1993-06-14	1999-02-02	Basf Aktiengellschaft	Animals transgenic for a tetracycline-regulated transcriptional inhibitor
EP0667912B1 (fr)	1993-07-13	2008-07-02	Centelion	Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5877399A (en) *	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
FR2718329B1 (fr) *	1994-03-21	2002-09-20	Rhone Poulenc Rorer Sa	Lapin transgénique sensibilisé aux dyslipoprotéinémies.
IL116816A (en)	1995-01-20	2003-05-29	Rhone Poulenc Rorer Sa	Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof

1999
- 1999-01-08 AU AU24536/99A patent/AU759707B2/en not_active Ceased
- 1999-01-08 DE DE69926729T patent/DE69926729T2/de not_active Expired - Lifetime
- 1999-01-08 AT AT99904051T patent/ATE302267T1/de active
- 1999-01-08 US US09/227,701 patent/US6512161B1/en not_active Expired - Lifetime
- 1999-01-08 WO PCT/US1999/000401 patent/WO1999035241A1/en active IP Right Grant
- 1999-01-08 DK DK99904051T patent/DK1049767T3/da active
- 1999-01-08 EP EP99904051A patent/EP1049767B1/en not_active Expired - Lifetime
- 1999-01-08 CA CA002316808A patent/CA2316808C/en not_active Expired - Fee Related
- 1999-01-08 PT PT99904051T patent/PT1049767E/pt unknown
- 1999-01-08 JP JP2000527627A patent/JP2002500039A/ja active Pending
- 1999-01-08 ZA ZA9900133A patent/ZA99133B/xx unknown
- 1999-01-08 ES ES99904051T patent/ES2247780T3/es not_active Expired - Lifetime
2009
- 2009-09-28 JP JP2009223202A patent/JP2010000090A/ja active Pending

Also Published As

Publication number	Publication date
CA2316808C (en)	2007-04-10
AU2453699A (en)	1999-07-26
WO1999035241A9 (en)	2000-04-13
ES2247780T3 (es)	2006-03-01
DE69926729T2 (de)	2006-06-08
EP1049767B1 (en)	2005-08-17
US6512161B1 (en)	2003-01-28
JP2002500039A (ja)	2002-01-08
WO1999035241A1 (en)	1999-07-15
EP1049767A4 (en)	2002-05-08
EP1049767A1 (en)	2000-11-08
DE69926729D1 (de)	2005-09-22
PT1049767E (pt)	2005-10-31
JP2010000090A (ja)	2010-01-07
CA2316808A1 (en)	1999-07-15
AU759707B2 (en)	2003-04-17
DK1049767T3 (da)	2005-09-19
ATE302267T1 (de)	2005-09-15

Publication	Publication Date	Title
ZA99133B (en)	1999-09-16	Transgenic rabbit that expresses a functional human lipoprotein (A).
DE69323983D1 (de)	1999-04-22	Methode zur Modifizierung des Fettdruckes von Buchstaben
DE60126933D1 (de)	2007-04-12	Verfahren zur fermentativen herstellung von l-threonine
DE69328025D1 (de)	2000-04-13	Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE69704855D1 (de)	2001-06-21	Induktionsheizgerät zur oberflächenbehandlung von zahnrädern
DE69433243D1 (de)	2003-11-20	Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE230414T1 (de)	2003-01-15	Mimetika von beta-faltblatt und verfahren zur verwendung davon
ZA9894B (en)	1998-07-08	Specific inhibitors of pancreatic lipase and their applications
ATE417504T1 (de)	2009-01-15	Verfahren zur bekämpfung von käfern
DE68911132D1 (de)	1994-01-13	Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin-profils.
DE69532725D1 (de)	2004-04-22	Methode zur direkter klonierung von nukleasegenen in e.coli
GB9905218D0 (en)	1999-04-28	Neurodegenerative disorder related gene
ATE288498T1 (de)	2005-02-15	Methoden zur inhibierung von helicobacter pylori
BR9709264A (pt)	1999-08-10	Processo para produzir e composto
DE68915214D1 (de)	1994-06-16	Methode zur Bestimmung des Pyrogengehaltes.
DE69311656D1 (de)	1997-07-24	Methode zur kontrolle des bräunungsverfahrens mittels edelgasen
DE50004899D1 (de)	2004-02-05	Verfahren zur Verringerung des Chlorgehaltes von organischen Isocyanaten
DE60224280D1 (de)	2008-02-07	Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
DE69521281D1 (de)	2001-07-19	Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
DE59300976D1 (de)	1996-01-04	Verfahren zur Verminderung des Halogengehaltes von polyhalogenierten Aromaten.
NZ514691A (en)	2004-02-27	Method to type prion proteins
DE69704220D1 (de)	2001-04-19	Synergistische fungizide Mischungen zur Bekämpfung von Pflanzenkrankheiten
ZA989313B (en)	2000-04-13	Novel compounds for treating diseases associated with the biological effect of endothelin.
NO964894D0 (no)	1996-11-18	Rekombinante viruser, deres fremstilling samt anvendelse av genterapi
ES2122912A1 (es)	1998-12-16	Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.